# S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial

Submission date	Recruitment status	Prospectively registered		
12/02/2004	No longer recruiting	☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
13/02/2004	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
16/08/2011	Musculoskeletal Diseases			

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Wadie Najm

#### Contact details

101 The City Drive Bldg 200 #512, Rt81 Orange United States of America 92868

# Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

HS#2000-1046

# Study information

## Scientific Title

## Study objectives

Not provided at time of registration

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

# Study type(s)

Treatment

### Participant information sheet

## Health condition(s) or problem(s) studied

Arthritis

#### **Interventions**

Participants were randomised to receive SAMe or Celebrex over two months. Pain, quality of life and musculoskeletal measures were assessed before, during and after the study.

## Intervention Type

Drug

#### Phase

**Not Specified** 

## Drug/device/biological/vaccine name(s)

S-Adenosyl methionine (SAMe), celecoxib

## Primary outcome measure

Not provided at time of registration

## Secondary outcome measures

Not provided at time of registration

## Overall study start date

01/09/2000

# Completion date

01/09/2002

# **Eligibility**

# Key inclusion criteria

Volunteers

## Participant type(s)

**Patient** 

## Age group

**Not Specified** 

#### Sex

**Not Specified** 

# Target number of participants

61

## Key exclusion criteria

Not provided at time of registration

## Date of first enrolment

01/09/2000

## Date of final enrolment

01/09/2002

# **Locations**

## Countries of recruitment

United States of America

# Study participating centre 101 The City Drive

Orange United States of America 92868

# Sponsor information

## Organisation

University of California, Irvine, Medical Center (UCIMC) (USA)

## Sponsor details

300 University Tower Irvine United States of America 92697

## Sponsor type

Hospital/treatment centre

#### **ROR**

https://ror.org/00cm8nm15

# Funder(s)

## Funder type

Hospital/treatment centre

## **Funder Name**

University of California, Irvine, Medical Center (UCIMC) (USA)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	26/02/2004		Yes	No